Tag: AXN

3rd Quarter 2017 – Growth Portfolio Update

3rd Quarter 2017 – Growth Portfolio Update

AXN – As mentioned in the recent Aoxing Pharmaceutical blog, I ended my position in this stock as the company announced a delisting of their common stock. The remaining proceeds have been reinvested into 22nd Century Group and TransEnterix Inc. OBCI – Continuing to hold steady in this growth stock as it tracks towards $6.…

Read More Read More

Aoxing Pharmaceutical Company – AXN

Aoxing Pharmaceutical Company – AXN

The end of the road has been reached for this company! And I have to say, it will not be missed. Today, AXN has announced a deregistration of their common stock and eventual delisting. The main reason for this action gravitating towards the company’s financial woes. So, what are some takeaways? A lack of communication…

Read More Read More

Aoxing Pharmaceutical Company – AXN

Aoxing Pharmaceutical Company – AXN

The Chinese Pharmaceutical landscape is chock full of companies. Many with cutting edge developments and growing revenues. In particular, the demand for pain management medication is growing as the culture is slowly transitioning from one rooted in traditional beliefs and herbal therapies to one of pills and operations. I’m attributing this trend to advancements in…

Read More Read More